Recent Updates
Recently added Catalysts

Follitropin beta

Phase 1

Ovarian Function Insufficiency | Small molecule | Other |Organon & Co.|Last Updated: Jan 9, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
ACTIVE_CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment6
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05330130Impact of FSH Dosage During Ovarian Stimulation for IVF/ICSI in Granulosa CellsPHASE1 COMPLETED 6Jul 5, 2023Jun 30, 2024Jan 9, 20251 United Arab Emirates
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of FSHR- and LHR of the GC, obtained from one follicle on the morning of day 5, before the administration of the first GnRH-antagonist, punctured during the ovarian stimulation cycle
5 days
Number of FSHR- and LHR of the GC, obtained from tone follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm, punctured during the ovarian stimulation cycle
1 day
Number of FSHR- and LHR of the GC, obtained from two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation, punctured during the ovarian stimulation cycle
1 day
Number of FSHR- and LHR of the GC, obtained from the follicular fluid of follicles aspirated during OPU
1 day
Secondary Endpoints
Level of E2 hormone in the blood, the morning of day 5, before the administration of the first GnRH-antagonist
5 days
Level of P4 hormone in the blood, the morning of day 5, before the administration of the first GnRH-antagonist
5 days
Level of FSH hormone in the blood, the morning of day 5, before the administration of the first GnRH-antagonist
5 days
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Daily 150 IU recFSHACTIVE_COMPARATORFollitropin beta injection 150 IU daily
Daily 300 IU recFSHACTIVE_COMPARATORFollitropin beta injection 300 IU daily
Interventions
NameTypeDescription
Follitropin beta injection 150 IUDRUGParticipants commence ovarian stimulation on day 2 or 3 of their menstrual cycle with a daily dosage of 150 IU rec-FSH. The dosage will remain constant throughout the course of the stimulation. From the morning of the 5th stimulation day, GnRH-antagonist will be administered daily to prevent LH-rise. As soon as ≥ 3 follicle of a size of 17mm are seen, 0.3 mg GnRH-Agonist will be administered for final oocyte maturation. During ovarian stimulation, follicle puncture procedures with the aspiration of follicular fluid will be performed at the following time: * one follicle on the morning of day 5, before the administration of the first GnRH-antagonist * one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm * two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation. Oocyte retrieval of all other follicles will be carried out 36 hours after injection of the medication for final oocyte maturation.
Follitropin beta injection 300 IUDRUGParticipants commence ovarian stimulation on day 2 or 3 of their menstrual cycle with a daily dosage of 300 IU rec-FSH. The dosage will remain constant throughout the course of the stimulation. From the morning of the 5th stimulation day, GnRH-antagonist will be administered daily to prevent LH-rise. As soon as ≥ 3 follicle of a size of 17mm are seen, 0.3 mg GnRH-Agonist will be administered for final oocyte maturation. During ovarian stimulation, follicle puncture procedures with the aspiration of follicular fluid will be performed at the following time: * one follicle on the morning of day 5, before the administration of the first GnRH-antagonist * one follicle of the size of 12 to 14 mm, when at least 2 to 3 follicles have reached a size of 12 to 14 mm * two follicles (= pre-ovulatory follicle) on the morning of the day of final oocyte maturation. Oocyte retrieval of all other follicles will be carried out 36 hours after injection of the medication for final oocyte maturation.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 38 Years
SexFEMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Desire to perform oocyte freezing for social fertility preservation, age 18 - 38 years * BMI of 18-32 kg/m2 * Regular menstrual cycles with a length of 24-35 days * Anti-Muellerian-Hormone levels between 1.3 - 6.25 ng/ml (Ferraretti and Gianaroli, 2014; Calzada et al., 2019) ...

Countries:United Arab Emirates
Unlock Eligibility Criteria